超声引导下骶管麻醉在宫颈癌腔内和/或间质近距离放射治疗中的临床价值。
The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer.
发表日期:2024 Sep 26
作者:
Xiaojing Yang, Chen Li, Zhen Li, Dongping Du, Jie Fu
来源:
GYNECOLOGIC ONCOLOGY
摘要:
目的探讨超声引导下骶管麻醉用于宫颈癌患者腔内和/或间质近距离治疗的有效性和安全性。对12月7日以来我科220例患者共1039例腔内和/或间质近距离治疗进行回顾性分析。 2020年至2024年3月21日。该研究评估了麻醉满意度、生命体征变化、麻醉起效时间、麻醉药物用量、麻醉持续时间以及不良反应发生率。麻醉满意度为73.8%。麻醉前后患者心率(HR)、平均动脉压(MAP)、收缩压(SBP)或血氧饱和度(SaO2)均无显着差异(P>0.05)。麻醉起效时间20~35分钟,麻醉药平均用量20ml,麻醉持续时间30~120分钟。严重不良反应包括2例麻醉后晕厥(与骶骨囊肿相关)。恶心的发生率为2.2%,呕吐、尿潴留、心动过缓、肛门不适、头晕等其他不良反应的总发生率低于1%。超声引导骶管麻醉显示出显着的优势,包括有效的麻醉、对生命体征影响极小,起效快,维持时间长,不良反应发生率低。建议广泛应用于宫颈癌患者的腔内和/或间质近距离放射治疗。版权所有 © 2024 作者。由爱思唯尔公司出版。保留所有权利。
To explore the effectiveness and safety of ultrasound-guided sacral anesthesia in intracavitary and/or interstitial brachytherapy for cervical cancer patients.A retrospective analysis was conducted on a total of 1039 intracavitary and/or interstitial brachytherapy involving 220 patients in our department from December 7, 2020 to March 21, 2024. The study assessed the satisfaction with anesthesia, changes in vital signs, onset time of anesthesia, dosage of anesthetic drugs, duration of anesthesia, and incidence of adverse reactions.The rate of satisfaction with anesthesia was 73.8 %. There were no significant differences in patients' heart rate (HR), mean arterial pressure (MAP), systolic blood pressure (SBP), or oxygen saturation (SaO2) before and after anesthesia (P > 0.05). The onset time of anesthesia ranged from 20 to 35 min, the average dosage of anesthetic was 20 ml, and the duration of anesthesia lasted from 30 to 120 min. Serious adverse reactions included 2 cases of post-anesthesia syncope (associated with sacral cysts). The incidence of nausea was 2.2 %, and the total incidence of other adverse reactions, such as vomiting, urinary retention, bradycardia, anal discomfort, and dizziness, was less than 1 %.Ultrasound guided sacral anesthesia demonstrates significant advantages, including effective anesthesia, minimal impact on vital signs, rapid onset, prolonged maintenance, and a low incidence of adverse reactions. It is recommended for widespread application in intracavitary and/or interstitial brachytherapy for cervical cancer patients.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.